Liver cirrhosis is the end stage of chronic liver inflammation and fibrosis. Once cirrhosis is established, the liver architecture is permanently altered — but with the right management, disease progression can be halted, complications prevented, and survival significantly extended. In decompensated cirrhosis, specialist hepatology input determines whether a patient recovers to a compensated state or deteriorates toward liver failure.
This article explains cirrhosis, its causes in India, how it is graded, and what specialist treatment in Mumbai involves.
What is liver cirrhosis?
Cirrhosis is diffuse hepatic fibrosis with nodule formation — the liver’s normal architecture replaced by scar tissue. It is the final common pathway of chronic liver injury regardless of cause. The liver loses its regenerative capacity and its ability to perform key functions: protein synthesis (albumin, clotting factors), detoxification, bile production, and glucose regulation.
Compensated cirrhosis: The liver maintains adequate function. Patients may be asymptomatic or mildly symptomatic. Without treatment of the underlying cause, progression to decompensation is inevitable — at a rate of approximately 5–10% per year.
Decompensated cirrhosis: The liver can no longer maintain function. Defined by the appearance of: ascites (fluid in abdomen), variceal bleeding (from oesophageal or gastric varices), hepatic encephalopathy (confusion, altered consciousness), or jaundice with coagulopathy. Each decompensation event carries significant mortality and marks a transition point where liver transplant evaluation should begin.
Causes of cirrhosis in India
- Alcohol-related liver disease (ALD) — the leading cause in urban India; cirrhosis develops after 10–15 years of heavy drinking in susceptible individuals
- Hepatitis B (HBV) — India has an intermediate endemicity of ~3.5%; HBV-related cirrhosis is common, particularly in men over 40
- Hepatitis C (HCV) — less prevalent than HBV but increasing; now curable with direct-acting antivirals (DAAs)
- MASLD/NASH — metabolic-associated steatotic liver disease; the fastest-growing cause of cirrhosis in India, driven by obesity, type 2 diabetes, and metabolic syndrome
- Autoimmune hepatitis (AIH) — more common in women; treatable with immunosuppression if caught early
- Wilson’s disease — hereditary copper overload; causes cirrhosis in young patients if untreated
- Cryptogenic cirrhosis — no identifiable cause after complete workup; often represents burned-out NASH or undetected autoimmune disease
Grading cirrhosis — Child-Pugh and MELD
Child-Pugh score (A/B/C) assesses five parameters: bilirubin, albumin, INR, ascites, and encephalopathy. Child-Pugh A = compensated; Child-Pugh C = severely decompensated, 1-year survival without transplant approximately 35–45%.
MELD score (Model for End-Stage Liver Disease) uses bilirubin, creatinine, and INR to estimate 90-day mortality. MELD ≥15 is the threshold at which liver transplant is considered to offer survival benefit. MELD 3.0 (the updated version incorporating sodium and sex) is now standard in transplant listing.
These scores guide treatment intensity and transplant listing decisions — they should be calculated and interpreted by a trained hepatologist, not just generated by an online calculator.
Complications of cirrhosis — specialist management
Ascites
First-line: sodium restriction and diuretics (spironolactone ± furosemide). Refractory ascites (not responding to diuretics): large-volume paracentesis with albumin infusion, TIPS evaluation, or transplant listing. Spontaneous bacterial peritonitis (SBP) — a life-threatening infection of ascitic fluid — requires prompt diagnosis by paracentesis and empirical antibiotics. Secondary prophylaxis with norfloxacin is mandatory after a first SBP episode.
Variceal bleeding
Medical: terlipressin or somatostatin analogues plus early endoscopy (within 12 hours). Endoscopic: band ligation for oesophageal varices. Secondary prophylaxis: non-selective beta-blockers (propranolol or carvedilol) plus repeated band ligation. TIPS for refractory or early re-bleeding. Failure of TIPS = transplant indication.
Hepatic encephalopathy
Precipitant identification and treatment (infection, bleeding, electrolyte disturbance, constipation). Lactulose titrated to 2–3 soft stools per day. Rifaximin for recurrent or persistent encephalopathy. Zinc supplementation. Nutritional support — adequate protein (1.2–1.5 g/kg/day) is essential; protein restriction is harmful and outdated.
Hepatorenal syndrome (HRS)
HRS-AKI: terlipressin + albumin is the treatment of choice (EASL 2018; AASLD). Early diagnosis critical — serum creatinine rise in a cirrhotic patient requires prompt assessment for HRS vs. pre-renal vs. intrinsic renal disease. HRS-CKD: renal function may not recover; transplant is the definitive treatment.
Cirrhosis and liver transplant — when to refer
Liver transplant evaluation should be initiated — not deferred — when:
- MELD ≥15 or Child-Pugh C
- First episode of SBP (indicates significantly impaired immunity and prognosis)
- Refractory ascites requiring frequent paracentesis
- Recurrent variceal bleeding despite secondary prophylaxis
- Hepatic encephalopathy requiring hospitalisation
- HCC within Milan criteria (transplant is curative in selected patients)
In India, LDLT is the dominant modality. A family member or spouse can donate a lobe of their liver. The hepatologist’s role is to evaluate the recipient’s candidacy, assess the donor, and manage the patient through the transplant process and beyond.
Dr. Chetan Kalal provides complete cirrhosis management at Gleneagles Hospital Mumbai — from diagnosis and cause identification through complication management, MELD-based transplant listing, LDLT evaluation, and post-transplant long-term care. Virtual consultations are available for patients from any Indian city or internationally.
Frequently Asked Questions
Can liver cirrhosis be reversed?
Early-stage fibrosis (F1–F2) can regress with treatment of the underlying cause. Established cirrhosis (F4) does not reverse — but disease progression can be arrested, and with effective treatment of the cause (antiviral therapy for HBV/HCV, alcohol abstinence for ALD, weight loss for MASLD), patients can remain in compensated cirrhosis indefinitely. Decompensated cirrhosis requires specialist management and often transplant evaluation.
Who is the best cirrhosis specialist in Mumbai?
Dr. Chetan Kalal — DM (Hepatology), MD (Medicine), MRCP (UK), Associate Director Hepatology at Gleneagles Hospital Mumbai — manages the complete spectrum of cirrhosis from diagnosis through transplantation. He is the first DM Hepatologist of Maharashtra with 26+ PubMed publications and APASL-AARC consortium membership.
What is the life expectancy with liver cirrhosis?
Compensated cirrhosis: median survival >12 years with cause-specific treatment. Decompensated cirrhosis: median survival without transplant 1.8–3 years after first decompensation, depending on MELD score. Child-Pugh C without transplant: 1-year survival ~35–45%. These figures are averages — individual prognosis depends on cause, MELD score, complication control, and access to subspecialty care.
Is liver transplant the only treatment for cirrhosis?
No. Most cirrhosis patients do not need transplant. Treatment of the underlying cause, prevention of complications, and management of decompensation episodes can maintain quality of life for years. Transplant is indicated when MELD crosses the survival-benefit threshold (≥15) or when specific complications become refractory to medical management.
Book a Consultation
In-person, Mumbai: Gleneagles Hospital — drchetankalal.com/book
Second opinion or virtual consult: drchetankalal.com/second-opinion · drchetankalal.com/virtual-consult
Medical disclaimer: This article is for informational and educational purposes only and does not constitute individual clinical advice. For personal clinical assessment, book a consultation with Dr. Chetan Kalal. In a liver emergency, attend the nearest emergency department immediately.
About the Author
Dr. Chetan Kalal — MBBS, MD (Internal Medicine), DM Hepatology (ILBS, New Delhi) — is the First DM Hepatologist of Maharashtra and Associate Director, Hepatology & Liver Transplant, at Gleneagles Hospital Mumbai. He has 26 peer-reviewed publications and serves on the APASL AARC Expert Panel. Fellow, National Academy of Medical Sciences (FNAMS). Learn more · Book appointment

